Toleranzia AB (TOL) - Total Liabilities
Based on the latest financial reports, Toleranzia AB (TOL) has total liabilities worth Skr9.54 Million SEK (≈ $1.03 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Toleranzia AB working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Toleranzia AB - Total Liabilities Trend (2012–2024)
This chart illustrates how Toleranzia AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Toleranzia AB.
Toleranzia AB Competitors by Total Liabilities
The table below lists competitors of Toleranzia AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Khind Holdings Bhd
KLSE:7062
|
Malaysia | RM126.37 Million |
|
GigaMedia Limited
F:GIFN
|
Germany | €3.82 Million |
|
Observe Medical Asa
OL:OBSRV
|
Norway | Nkr71.21 Million |
|
Scienture Holdings, Inc.
NASDAQ:SCNX
|
USA | $23.63 Million |
|
YXT.COM GROUP HOLDING LIMITED American Depository Shares
NASDAQ:YXT
|
USA | $339.61 Million |
|
Minbos Resources Ltd
AU:MNB
|
Australia | AU$2.11 Million |
|
M.P.Evans Group
LSE:MPE
|
UK | GBX60.30 Million |
|
Picard Medical, Inc.
NYSE MKT:PMI
|
USA | $18.76 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Toleranzia AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See TOL net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Toleranzia AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Toleranzia AB (2012–2024)
The table below shows the annual total liabilities of Toleranzia AB from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr6.40 Million ≈ $688.74K |
-7.37% |
| 2023-12-31 | Skr6.91 Million ≈ $743.52K |
+12.84% |
| 2022-12-31 | Skr6.12 Million ≈ $658.93K |
+43.59% |
| 2021-12-31 | Skr4.26 Million ≈ $458.91K |
-8.33% |
| 2020-12-31 | Skr4.65 Million ≈ $500.64K |
+26.95% |
| 2019-12-31 | Skr3.66 Million ≈ $394.37K |
+30.76% |
| 2018-12-31 | Skr2.80 Million ≈ $301.59K |
+33.09% |
| 2017-12-31 | Skr2.11 Million ≈ $226.61K |
-5.39% |
| 2016-12-31 | Skr2.23 Million ≈ $239.52K |
-20.67% |
| 2015-12-31 | Skr2.81 Million ≈ $301.95K |
+97.90% |
| 2014-12-31 | Skr1.42 Million ≈ $152.58K |
+48.89% |
| 2013-12-31 | Skr952.25K ≈ $102.48K |
-47.33% |
| 2012-12-31 | Skr1.81 Million ≈ $194.57K |
-- |
About Toleranzia AB
Toleranzia AB (publ), a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate in clinical trial for treating myasthenia gravis, an autoimmune nerve and muscle disease. The company also develops TOL3 drug candidate for the treatment of ANCA vasculitis, an autoimmune blood vessel disease. In … Read more